Blair William & Co. IL Has $6.04 Million Position in Becton, Dickinson and Company $BDX

Blair William & Co. IL lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 6.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,036 shares of the medical instruments supplier’s stock after selling 2,230 shares during the quarter. Blair William & Co. IL’s holdings in Becton, Dickinson and Company were worth $6,035,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company in the first quarter valued at $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company in the first quarter valued at $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $29,000. Cornerstone Planning Group LLC lifted its stake in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $31,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $186.41 on Monday. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $190.07 and a two-hundred day simple moving average of $185.73. The stock has a market capitalization of $53.43 billion, a price-to-earnings ratio of 33.53, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,023 shares of company stock worth $562,036. Insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Piper Sandler restated a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price for the company. Finally, Argus raised their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.